Published in Gene Therapy Weekly, January 25th, 2007
Study 1: New research, "Targeting the active beta-catenin pathway to treat cancer cells," is the subject of a report. According to a study from Israel, "The adenomatous polyposis coli or beta-catenin genes are frequently mutated in colorectal cancer cells, resulting in oncogenic activation of beta-catenin signaling. We tried to establish in vitro and in vivo models for selectively killing human cancer cells with an activated beta-catenin/T-cell factor (Tcf) pathway."
"We used a recombinant adenovirus that carries a lethal gene [p53-up-regulated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-01-25)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.